Enalapril
- Generic Name
- Enalapril
- Brand Names
- Epaned, Vaseretic, Vasotec, Aqumeldi
- Drug Type
- Small Molecule
- Chemical Formula
- C20H28N2O5
- CAS Number
- 75847-73-3
- Unique Ingredient Identifier
- 69PN84IO1A
- Background
Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypertensive agent that suppresses the renin-a...
- Indication
Indicated for the management of essential or renovascular hypertension as monotherapy or in combination with other antihypertensive agents, such as thiazide diuretics, for an additive effect.
Indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis.
...
- Associated Conditions
- Diabetic Nephropathy, Hypertension, Symptomatic Congestive Heart Failure, Asymptomatic Left ventricular dysfunction
- Associated Therapies
- -
Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis
- First Posted Date
- 2018-05-16
- Last Posted Date
- 2018-05-16
- Target Recruit Count
- 40
- Registration Number
- NCT03526042
- Locations
- 🇲🇽
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
H-Type Hypertension Precision Medicine Trial
- Conditions
- Interventions
- First Posted Date
- 2018-03-21
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
- Target Recruit Count
- 3600
- Registration Number
- NCT03472508
- Locations
- 🇨🇳
Peking University First Hosptial, Beijing, China
🇨🇳Second Affiliated Hospital of Nanchang University, Nanchang, China
🇨🇳The First People's Hospital of Lianyungang, Lianyungang, China
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
- Conditions
- Interventions
- First Posted Date
- 2018-03-15
- Last Posted Date
- 2021-02-24
- Lead Sponsor
- Manchester University NHS Foundation Trust
- Target Recruit Count
- 118
- Registration Number
- NCT03466333
- Locations
- 🇬🇧
Manchester University NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom
Bariatric Surgery and Pharmacokinetics of Enalapril
- Conditions
- First Posted Date
- 2018-03-09
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- Norwegian University of Science and Technology
- Target Recruit Count
- 12
- Registration Number
- NCT03460366
- Locations
- 🇳🇴
St. Olavs University Hospital, Trondheim, Norway
PROACT: Can we Prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer and Lymphoma?
- First Posted Date
- 2017-08-29
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- South Tees Hospitals NHS Foundation Trust
- Target Recruit Count
- 111
- Registration Number
- NCT03265574
- Locations
- 🇬🇧
South Tees Hospitals NHS FT, Middlesbrough, Teesside, United Kingdom
The Effect of Neprilysin (LCZ696) on Exercise Tolerance in Patients With Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- University of Sao Paulo General Hospital
- Target Recruit Count
- 52
- Registration Number
- NCT03190304
- Locations
- 🇧🇷
Marcelo Rodrigues dos Santos, São Paulo, SP, Brazil
Comparing ARNI With ACE Inhibitor on Endothelial Function
- Conditions
- Interventions
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- Brigham and Women's Hospital
- Registration Number
- NCT03119623
A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
- First Posted Date
- 2017-02-28
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2572
- Registration Number
- NCT03066804
- Locations
- 🇬🇧
Novartis Investigative Site, York, United Kingdom
Genetic Determinants of ACEI Prodrug Activation
- First Posted Date
- 2017-02-13
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 21
- Registration Number
- NCT03051282
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2021-10-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 140
- Registration Number
- NCT02970669
- Locations
- 🇺🇸
Novartis Investigative Site, Tacoma, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.